Skip to content
TriangleGet started
← Aggressive B-Cell Non-Hodgkin Lymphoma

HEALTH PROFESSIONAL · SOURCE READING

Glofitamab

Source: Aggressive B-Cell Non-Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: May 12, 2025 · Captured 2026-09-09.

Selected source text with whitespace normalised. This Triangle page is not an NCI PDQ summary. Independent clinical review is pending.

Context: Treatment of Aggressive, Recurrent B-Cell Non-Hodgkin Lymphoma / Treatment Options for Aggressive, Recurrent B-Cell Non-Hodgkin Lymphoma / Bispecific T-cell engagers

Glofitamab is a CD20-directed BiTE with bivalency for CD20. It is given intravenously every 21 days for a maximum of 12 cycles with weekly step-up dosing during cycle 1.

Evidence (glofitamab):

A phase I/II trial included 155 patients with relapsed or refractory DLBCL after two or more prior lines of therapy.[39]

Source links and citations

A phase I/II trial included 155 patients with relapsed or refractory DLBCL after two or more prior lines of therapy.[39]

With a median follow up of 12.6 months, the overall response rate was 52% (95% CI, 43%–60%), and the complete response rate was 39% (95% CI, 32%–48%).[39][Level of evidence C3]

Source links and citations

A phase I/II trial included 155 patients with relapsed or refractory DLBCL after two or more prior lines of therapy.[39]

The median PFS was 4.9 months (95% CI, 3.4–8.1).

A phase I/II trial included 155 patients with relapsed or refractory DLBCL after two or more prior lines of therapy.[39]

The estimated 12-month OS rate was 50% (95% CI, 41%–58%).

A phase I/II trial included 155 patients with relapsed or refractory DLBCL after two or more prior lines of therapy.[39]

Cytokine release syndrome occurred in 63% of patients, and it was grade 3 or higher in 4% of patients. ICANS occurred in 8% of patients, and it was grade 3 or higher in 3% of patients.

A phase I/II trial included 155 patients with relapsed or refractory DLBCL after two or more prior lines of therapy.[39]

Results were not significantly different among 52 recipients of prior CD19-directed CAR T-cell therapy.

Publication references

Read the original reference and check its publication notices.

Preserved source evidence · Independent clinical review pending · Not medical advice